Relmada Shares Defy Positive Results with Sharp Decline

In a surprising market development, Relmada Therapeutics witnessed its stock value drop by more than 3% during premarket trading. This decline occurred despite the company reporting financial performance that exceeded expectations and announcing groundbreaking clinical trial data for its lead program. Investors appeared to overlook both the significantly reduced net loss and compelling efficacy demonstrated in bladder cancer treatment, creating a puzzling disconnect between corporate progress and market reception.

Relmada’s third-quarter 2025 financial results revealed a net loss of $10.1 million, translating to a loss per share of $0.30. This figure substantially outperformed analyst projections of a $0.45 per share loss. Nevertheless, this positive earnings surprise failed to prevent the company’s shares from Read more...